Skip to content

uniQure QURE Purchases of fixed maturity securities

Purchases of fixed maturity securities at other companies

TG Therapeutics logo
TG TherapeuticsTGTX
$21.06M-77.1%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.

The official record: uniQure’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's purchases of fixed maturity securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's purchases of fixed maturity securities?
uniQure (QURE) reported purchases of fixed maturity securities of $441.25M in Q4 2025.
How has uniQure's purchases of fixed maturity securities changed year-over-year?
uniQure's purchases of fixed maturity securities increased by 449.8% year-over-year, from $80.26M to $441.25M.
What does purchases of fixed maturity securities mean?
Cash spent purchasing fixed-income securities (bonds, notes, debentures) for the investment portfolio.